Keywords
Biguanide
Type 2 Diabetes Mellitus
Narrative review
Sulfonylurea
How to Cite
Abstract
Diabetes Mellitus requires long-term management at a considerable cost. Therefore, a cost-Effectiveness analysis was used to assess several health interventions. Biguanide and Sulfonylurea provided the best results at the cheapest cost in this study. This study aims to gain a supporting theoretical foundation regarding the cost-effectiveness of using oral antidiabetic drugs biguanide and sulfonylureas in patients with type 2 diabetes mellitus. The method used in this study is a Narrative Review using literature that discusses the cost-effectiveness of oral antidiabetic drugs biguanide and sulfonylureas in patients with type 2 diabetes mellitus. Based on the results of this study, the age range of the occurrence of Type 2 Diabetes Mellitus is 45-65 years, with more percentage of male patients than women and a common complication is hypertension. In this study, the use of the biguanide drug (Metformin) was shown to provide a significant reduction in blood sugar levels at a reasonably low cost. The ICER results showed that combination drugs increased additional costs, but their use was more effective in healing and improving patients' quality of life. In conclusion to this study, the use of biguanide and sulfonylurea groups proved cost-effective compared to other antidiabetic drugs.
References
American Diabetes Association. Introduction: Standards of Medical Care in Diabetes. Diabetes Care. 2018;41(Suppl 1): S1–2.
International Diabetes Federation. IDF DIABETES ATLAS 8th. IDF Diabetes Atlas, 8th Ed. 2017;1–150.
Kemenkes RI. Situation and analysis of diabetes. Pus Data and Inf Kesehat RI Ministry. 2014;2.
Agency for Health Research and Development. Basic Health Research 2018. Kemenkes RI, Jakarta. 2018;
Andayani TM. Pharmacoeconomics principles and methodologies. Yogyakarta Bursa Ilmu. 2013;3–37.
Ferrari R. Writing narrative style literature reviews. Med Writ. 2015;24(4):230–5.
Tandon T, Dubey AK, Srivastava S, Manocha S, Arora E, Hasan N. A pharmacoeconomic analysis to compare the cost-effectiveness of Metformin plus teneligliptin with Metformin plus Glimepiride in patients of type-2 diabetes mellitus. J Fam Med Prim Care. 2019;8( 3):955.
Dhakal S, Shakya S, Sharma SK. Cost-Effectiveness Analysis of Oral Hypoglycemics for Type-2 Diabetes Mellitus at a Tertiary Care Hospital, Nepal. J Pharm Pharmacol. 2019;7:546–56.
Permsuwan U, Dilokthornsakul P, Saokaew S, Thavorn K, Chaiyakunapruk N. Cost-effectiveness of dipeptidyl peptide-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand. Clin outcomes Res CEOR. 2016;8:521.
Nian H, Wan X, Ma J, Jie F, Wu B. Economic evaluation of dapagliflozin versus Metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise. Cost Eff Resour Alloc. 2020;18(1):1–10.
Wulandari AA, Revina R, Pradana DLC. The Cost of Using Oral Hypoglycemic Drugs (OHO) Metformin and Glimepiride in Patients with Type II Outpatient Type II Diabetes Mellitus Non-BPJS in Serang 2018, Is No Different Significantly. J Insa Farm Indones. 2020;3(1):50–5.
Romadhoni HA, Harlianti MS. Cost-Effectiveness Analysis of Use Between Metformin and Glimepiride In People with Type 2 Outpatient Diabetes Mellitus at PKU Muhammadiyah Delanggu Hospital 2016. University of Muhammadiyah Surakarta; 2018.
Laelasari E, Sauriasari R, Banun A. Cost-Effectiveness Analysis of Insulin, Sulfonylurea, and Sulfonylurea--Metformin In Type 2 Diabetes Mellitus. Asian J Pharm Clin Res. 2017;10(Special Issue October):50–3.
Indonesian Endocrinology Society. Consensus on the management and prevention of type 2 diabetes mellitus in Indonesia 2015. PB PERKENI. 2015;
Riyanti RA. Cost-Effective Analysis of Oral Metformin and Glimepiride Antidiabetics in Patients with Type 2 Diabetes Mellitus Hospitalization Pandan Charcoal Boyolali Hospital in 2016. Setia Budi Surakarta University; 2017.
Indonesian Endocrinology Society. Consensus on dyslipidemia management in Indonesia. Jakarta Pus Pnb Disease Science in Fak Kedokt UI. 2012;
Budiman B, Sihombing R, Pradina P. Relationship of dyslipidemia, hypertension and diabetes mellitus with the incidence of acute myocardial infarction. J Kesehat Masy Andalas. 2017;10(1):32–7.
Arnold RJG. Pharmacoeconomics: from theory to practice. CRC Press; 2016.
Jia Y, Lao Y, Zhu H, Li N, Leung S-W. Is Metformin still the most efficacious first-line oral hypoglycaemic drug in treating type 2 diabetes? A network meta-analysis of randomized controlled trials. Obes Rev. 2019;20(1):1–12.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Kezia Ivana, Dhigna Luthfiyani Citra Pradana, Citra Ayu Aprilia